Lofexidine Tablet
Product Images NDC 70954-909

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lofexidine (NDC 70954-909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label-1 (Container 1)

Lofexidine Tablets 0.18 mg oral tablets label contains 36 tablets per bottle. Distributed by ANI Pharmaceuticals, Inc. The label includes storage instructions to protect from heat and moisture and keep the bottle tightly closed. It also states to keep medication out of reach of children and includes a barcode and expiration details.*

FDA Label Image

Label-2 (Container 2)

Lofexidine Tablets 0.18 mg label from ANI Pharmaceuticals, Inc. for a package of 96 oral tablets. The label includes storage instructions, dosage strength of 0.18 mg per tablet (equivalent to 0.2 mg lofexidine hydrochloride), and warnings to keep out of reach of children. Also displays the NDC 70954-909-20, batch information, and barcode.*

FDA Label Image

Graph4 (Graphfour)

A line graph depicting the mean SWS Gossage Score over a 5-day study period comparing Lofexidine 2.88 mg and placebo. The x-axis represents the study days from 1 to 5, and the y-axis shows scores ranging approximately from 1 to 15. Two lines with error bars illustrate the 95% confidence intervals for each group.*

FDA Label Image

Graphone (Graphone)

A survival-type curve chart showing the proportion of subjects completing the treatment period over study days 1 to 7. The chart compares outcomes for groups taking Lofexidine at 2.16 mg and 2.88 mg doses versus a placebo group. The vertical axis represents the proportion of subjects completing treatment, while the horizontal axis shows the study days.*

FDA Label Image

Graph-3 (Graphthree)

A Kaplan-Meier survival curve showing the proportion of subjects completing the treatment period over 8 study days. Two groups are compared: one receiving Lofexidine 2.88 mg (solid line) and the other receiving placebo (dashed line), with the Lofexidine group exhibiting a higher completion proportion throughout the study.*

FDA Label Image

Graph2 (Graphtwo)

A line graph displaying mean SOWS (Subjective Opiate Withdrawal Scale) Gossop Scores over a 7-day study period, comparing Lofexidine doses of 2.16 mg and 2.88 mg with placebo. The x-axis represents study days, and the y-axis shows mean scores with error bars representing 95% confidence intervals.*

FDA Label Image

Image-1 (Image 1)

A text panel listing side effects or symptoms such as low blood pressure, slow heartbeat, dizziness, lightheadedness, and feeling faint at rest or when standing up. The text is presented as bulleted points on a white background.*

FDA Label Image

Image-2 (Image 2)

A text panel listing potential symptoms including low blood pressure or related symptoms like lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. The content appears to be part of side effects or warnings for the medication Lofexidine.*

FDA Label Image

Structure (Structure)

Chemical structure of Lofexidine hydrochloride, showing the arrangement of chlorine, nitrogen, oxygen, and carbon atoms in the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.